Health ❯ Healthcare ❯ Clinical Trials

Phase 3 Trials

Efficacy Studies Eli Lilly Trials C-POST Trial Drug Efficacy DESTINY-Breast09 Trial MajesTEC-3 Study ASCENT-03 Trial Eli Lilly DeFi Trial EV-303 Trial SCORPIO-PEP Trial EMBER-3 Trial SEQUOIA-HCM SURMOUNT-OSA ASPEN Study MajesTEC-3 Trial HER2CLIMB-05 Trial Lecanemab Efficacy and Safety EPCORE FL-1 Trial Weight Loss Studies Brensocatib Clinical Trial Weight Loss Medications INDIGO Trial E. coli Vaccine Trials STRIDE-3 Study Diazoxide Choline Extended-Release Cognitive Decline Efficacy and Safety Studies DREAMM Trials Immunotherapy Trials KEYNOTE-689 Trial ROSELLA Study BREAKWATER Trial Novo Nordisk Study Study Results MARIPOSA and FLAURA2 Trials Vaccine Efficacy CheckMate-067 Destiny-Breast09 Study RUBY Trial KEYNOTE-905/EV-303 Trial CARTITUDE-4 Trial SERENA-6 ACHIEVE-1 Trial Weight Loss Drugs DREAMM-7 Trial VERITAC-2 Trial Placebo-Controlled Trials PURPOSE Trials TRONTIER Studies ADjoin Extension Trial Eli Lilly Studies H3 K27M-mutant Glioma Nucala Trials ACROSS 2 Trial Tonmya SEQUOIA and CLL14 Trials ESSENCE Trial EV-302 Trial Ecnoglutide Gepotidacin vs Nitrofurantoin Avexitide SUNMO Trial ACROSS 2 Study PATHFNDR Trials Clarity AD Trial Oasis Trials Osimertinib Study Eisai Co., Ltd. STELLAR Trial Analgesic Products Cytomegalovirus Vaccine BRUIN CLL-321 Trial Semaglutide 3475A-D77 Study IRAKLIA Trial Cagrilintide MOTION Study AURIGA Study STEP UP Trial Liver Disease Treatments PERSEUS and CEPHEUS Trials LIBERTY-CUPID Program KEYNOTE-689 ASC4FIRST Trial SOLARIS Trial Brepocitinib Antibody Therapy PROTOSTAR Study DESTINY-Breast12 Study IMforte Trial Oncology Trials BOND-003 Trial MINT Trial Psoriasis Treatments FIBRONEER-IPF Trial DESTINY-Breast05 Trial KAI-9531 Navenibart Clinical Development

FDA Grants Priority Review to Vera's Atacicept for IgA Nephropathy

The filing leans on interim ORIGIN 3 data showing significant proteinuria reductions at week 36.

Alumis TYK2 Pill Hits Phase 3 Goals in Psoriasis as Stock Jumps and $175 Million Offering Is Planned

FDA Grants Priority Review to Axsome’s AXS-05 for Alzheimer’s Agitation, Sets April 30 PDUFA Date

FDA Approves Aqvesme for Thalassemia Anemia, First U.S. Therapy for Both Patient Groups

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

FDA Grants National Priority Voucher to J&J’s Tecvayli–Darzalex Combo in Multiple Myeloma

FDA Approves Two First-in-Class Oral Treatments for Gonorrhea

Lilly’s Imlunestrant Data Show Stronger Results With Abemaciclib, Delayed Chemotherapy in ER+ Breast Cancer

FDA Approves Amgen’s Uplinza for Generalized Myasthenia Gravis

EU Regulator Backs Myqorzo for Obstructive Hypertrophic Cardiomyopathy

Preoperative MRI Fails to Improve Outcomes in Early HR-Negative Breast Cancer

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

FDA Approves One-Time Intrathecal Gene Therapy Itvisma for Older SMA Patients